On 31 January 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no. 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 2 billion in the period from 31 January 2008 to 6
August 2008.

Since the announcement as of 25 February 2008, the following
transactions have been made under the programme:

                  Number of shares Average purchase Transaction
                                        price       value, DKK
Accumulated, last          947,907                  305,277,248
25 Feb 2008                 30,000         347.1900  10,415,700
26 Feb 2008                 30,000         342.4500  10,273,500
27 Feb 2008                 50,000         338.1450  16,907,250
28 Feb 2008                 50,000         337.2500  16,862,500
29 Feb 2008                 50,000         335.4900  16,774,500
Accumulated, 2008        1,157,907                  376,510,698

Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 2,170 B-shares. The shares
in these transactions were not part of the Safe Harbour repurchase

With the transactions stated above, Novo Nordisk owns a total of
26,125,090 treasury shares, corresponding to 4.0% of the share
capital. The total amount of shares in the company is 646,960,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit

Further information:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
                       Tel: (+45) 4442 4765

In North America:      In North America:
Sean Clements          Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   cqfr@novonordisk.com

Stock Exchange Announcement no 13 / 2008